ViiV files monthly HIV jab in EuropeViiV Healthcare has submitted its once-monthly two-drug injectable therapy for HIV to the EMA, setting up possible approval Share XViiV files monthly HIV jab in Europehttps://pharmaphorum.com/news/viiv-files-monthly-hiv-jab-in-europe/
Republican revolt threatens Senate drug pricing billA bipartisan bill voted through by the Senate Finance Committee last week is under threat from a group Share XRepublican revolt threatens Senate drug pricing billhttps://pharmaphorum.com/news/republican-revolt-threatens-senate-drug-pricing-bill/
NICE backs funding for AZ’s Lynparza ovarian cancer maintenance therapyNICE has recommended interim funding on England’s NHS for AstraZeneca’s ovarian cancer drug Lynparza in the earlier stages Share XNICE backs funding for AZ’s Lynparza ovarian cancer maintenance therapyhttps://pharmaphorum.com/news/nice-backs-funding-for-azs-lynparza-ovarian-cancer-maintenance-therapy/
Sanofi licenses OTC Tamiflu rights for the US marketSanofi has made a bold play to bolster its consumer health business, licensing non-prescription rights to Roche’s influenza Share XSanofi licenses OTC Tamiflu rights for the US markethttps://pharmaphorum.com/news/sanofi-licenses-otc-tamiflu-rights-for-the-us-market/
Vertex presses go on its cystic fibrosis triple filingVertex has launched the next phase of its plan for the cystic fibrosis market, filing for approval of Share XVertex presses go on its cystic fibrosis triple filinghttps://pharmaphorum.com/news/vertex-presses-go-on-its-cystic-fibrosis-triple-filing/
Biohaven ALS drug blocked by FDA over manufacturing issueBiohaven’s therapy for amyotrophic lateral sclerosis (ALS) has been rejected by the FDA over manufacturing compliance issues for Share XBiohaven ALS drug blocked by FDA over manufacturing issuehttps://pharmaphorum.com/news/biohaven-als-drug-blocked-by-fda-over-manufacturing-issue/
NICE reviews number crunching methods as advanced technologies hit marketNICE is to review how it develops guidance on drugs, focusing on issues such as modifiers used in Share XNICE reviews number crunching methods as advanced technologies hit markethttps://pharmaphorum.com/news/nice-reviews-number-crunching-methods-as-advanced-technologies-hit-market/
Roche under pressure in US as Amgen/Allergan launch US cancer biosimilarsAmgen and Allergan have launched their cut-price biosimilar competitors to two big-selling cancer drugs from Roche in the Share XRoche under pressure in US as Amgen/Allergan launch US cancer biosimilarshttps://pharmaphorum.com/news/roche-under-pressure-in-us-as-amgen-allergan-launch-us-cancer-biosimilars/
FDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIBayer’s Gadavist has become the first imaging agent approved in the US to detect blockages in the hearts Share XFDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIhttps://pharmaphorum.com/news/fda-clears-bayers-gadavist-as-first-contrast-agent-for-cardiac-mri/
